Centre for Therapeutics Discovery
Translating research into lead stage therapeutic assets
Our Centre for Therapeutics Discovery (CTD), based in Mill Hill, translates innovative biology into lead stage therapeutic assets with clear pre-clinical and clinical developmental pathways.
We develop innovative assays and medicinal chemistry programmes from high quality hits in collaboration with scientists and clinicians from the MRC and other academic organisations, many of whom are world leaders in their field.
The Therapeutic Antibody Group (part of CTD) has substantial antibody engineering know-how, and can deliver humanized antibodies within 6 months.
What CTD provides
• A bridge over the gap between basic research and pre-clinical development
• Drug-like hits, leads and potential clinical candidates
• Our wealth of assay development experience, including novel target classes
• ‘Ready to run’ HTS assays that can be transferred to your screening facility
• State of the art computational chemistry, including in silico screening, pharmacophore mapping, template hopping and de novo design.
• Pharma quality medicinal chemistry and ADMET
• Collaborations with some of the world’s top scientists and opinion leaders for a wide range of targets
News feed
MRCT have recently launched a second collaboration with the University of Bristol in the area of pain medicine.
Substituted aminopyrimidine protein kinase B (PknB) inhibitors show activity against Mycobacterium tuberculosis
Researchers at the Breakthrough Breast Cancer Research Unit have used OPT imaging to measure changes in tumour volume.
Barbara Saxty has co-authored a Nature Communications paper entitled An intrinsically labile α-helix abutting the BCL9-binding site of β-catenin is required for its inhibition by carnosic acid.